GLP-1 receptor agonists are a class of molecules that bind to and activate the glucagon-like peptide-1 (GLP-1) receptor, a protein expressed in the pancreas, brain, gut, and other tissues. The class spans a wide range — from FDA-approved pharmaceutical drugs with well-characterized safety profiles to shorter research peptides studied in laboratory settings. Understanding what they share, and where they differ, is the starting point for making sense of public reporting on this category.
How researchers describe the mechanism
GLP-1 is a peptide hormone produced naturally in the gut in response to food intake. It stimulates insulin secretion in a glucose-dependent way, suppresses glucagon release, and — as research describes it — acts on receptors in the brain associated with appetite and satiety signaling. Native GLP-1 has a very short half-life in circulation because an enzyme called DPP-4 rapidly degrades it.
Pharmaceutical GLP-1 receptor agonists are engineered to resist that degradation. Different compounds take different approaches: some are structurally derived from the Gila monster peptide exendin-4, others are modified analogues of human GLP-1 itself. The net effect, as reported in clinical literature, is a molecule that continues to activate GLP-1 receptors for hours or days rather than minutes.
Tirzepatide adds a second target: it also agonizes the GIP receptor (glucose-dependent insulinotropic polypeptide). This dual-receptor mechanism is the subject of ongoing research comparing it to single-agonist approaches; researchers describe the dual action as potentially additive on certain metabolic signals, though the clinical picture is still being characterized.
FDA-approved compounds vs. research-grade analogues
The table below summarizes the main compounds commonly discussed in this class, distinguishing approved drugs from research-use peptides.
| Compound | Primary target(s) | Approximate half-life | Regulatory status (US) |
|---|---|---|---|
| Semaglutide | GLP-1R | ~7 days | FDA-approved (Ozempic, Wegovy, Rybelsus) |
| Liraglutide | GLP-1R | ~13 hours | FDA-approved (Victoza, Saxenda) |
| Tirzepatide | GLP-1R + GIPR | ~5 days | FDA-approved (Mounjaro, Zepbound) |
| Dulaglutide | GLP-1R | ~5 days | FDA-approved (Trulicity) |
| Exenatide | GLP-1R | ~2.4 hours (short-acting) | FDA-approved (Byetta, Bydureon) |
| Retatrutide | GLP-1R + GIPR + GcgR | Under investigation | Not approved — research only |
| CagriSema (cagrilintide + semaglutide) | GLP-1R + amylin receptor | Under investigation | Not approved — research only |
Research-grade analogues are synthesized peptides sold for laboratory and preclinical research use, not approved for human consumption. Studies in cell and animal models form the published literature on these compounds; human clinical data, where it exists, is from structured trials, not from general use.
What the approval record reflects
FDA approval of a GLP-1 receptor agonist reflects completion of a defined regulatory pathway: Phase I–III clinical trials, manufacturing standards, labeling review, and post-market surveillance obligations. The approved drugs above each have an indication — type 2 diabetes management and/or chronic weight management — and a defined prescribing context.
Research into the class continues to broaden. Published literature describes interest in cardiovascular outcomes (as reported following the SELECT trial for semaglutide), potential liver-related signals, and combinations with other peptide targets. Researchers also report on peptides such as retatrutide, which adds glucagon receptor agonism as a third mechanism. These are active areas of investigation; results from ongoing trials will determine which compounds, if any, move toward regulatory review.
Peptideone aggregates and summarizes what is publicly reported in the literature and from regulatory agencies. Nothing here constitutes medical advice, and research-grade compounds described above are not approved for human use.